AUTL
Price
$1.68
Change
+$0.04 (+2.44%)
Updated
Dec 24 closing price
Capitalization
447.12M
74 days until earnings call
Intraday BUY SELL Signals
BCYC
Price
$6.99
Change
+$0.05 (+0.72%)
Updated
Dec 24 closing price
Capitalization
484.88M
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AUTL vs BCYC

Header iconAUTL vs BCYC Comparison
Open Charts AUTL vs BCYCBanner chart's image
Autolus Therapeutics
Price$1.68
Change+$0.04 (+2.44%)
Volume$726.45K
Capitalization447.12M
Bicycle Therapeutics
Price$6.99
Change+$0.05 (+0.72%)
Volume$96.48K
Capitalization484.88M
AUTL vs BCYC Comparison Chart in %
AUTL
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AUTL vs. BCYC commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and BCYC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (AUTL: $1.68 vs. BCYC: $6.99)
Brand notoriety: AUTL and BCYC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 24% vs. BCYC: 31%
Market capitalization -- AUTL: $447.12M vs. BCYC: $484.88M
AUTL [@Biotechnology] is valued at $447.12M. BCYC’s [@Biotechnology] market capitalization is $484.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 1 FA rating(s) are green whileBCYC’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 1 green, 4 red.
  • BCYC’s FA Score: 1 green, 4 red.
According to our system of comparison, AUTL is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish while BCYC’s TA Score has 2 bullish TA indicator(s).

  • AUTL’s TA Score: 6 bullish, 4 bearish.
  • BCYC’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than BCYC.

Price Growth

AUTL (@Biotechnology) experienced а +7.69% price change this week, while BCYC (@Biotechnology) price change was +0.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

AUTL is expected to report earnings on Mar 10, 2026.

BCYC is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($485M) has a higher market cap than AUTL($447M). AUTL YTD gains are higher at: -28.511 vs. BCYC (-50.071). AUTL has higher annual earnings (EBITDA): -228.64M vs. BCYC (-245.86M). BCYC has more cash in the bank: 648M vs. AUTL (367M). BCYC has less debt than AUTL: BCYC (5.74M) vs AUTL (65.8M). AUTL has higher revenues than BCYC: AUTL (51.1M) vs BCYC (28.3M).
AUTLBCYCAUTL / BCYC
Capitalization447M485M92%
EBITDA-228.64M-245.86M93%
Gain YTD-28.511-50.07157%
P/E RatioN/AN/A-
Revenue51.1M28.3M181%
Total Cash367M648M57%
Total Debt65.8M5.74M1,146%
FUNDAMENTALS RATINGS
AUTL vs BCYC: Fundamental Ratings
AUTL
BCYC
OUTLOOK RATING
1..100
2867
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
4961
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (15) in the null industry is in the same range as AUTL (20) in the Biotechnology industry. This means that BCYC’s stock grew similarly to AUTL’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as AUTL (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to AUTL’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as AUTL (98) in the Biotechnology industry. This means that BCYC’s stock grew similarly to AUTL’s over the last 12 months.

AUTL's Price Growth Rating (49) in the Biotechnology industry is in the same range as BCYC (61) in the null industry. This means that AUTL’s stock grew similarly to BCYC’s over the last 12 months.

AUTL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that AUTL’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLBCYC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signal:
Gain/Loss:
BCYC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPGFX181.200.50
+0.28%
Mairs & Power Growth
BDAUX33.790.09
+0.27%
Baron Durable Advantage R6
SGSCX33.390.05
+0.15%
DWS Global Small Cap S
EEMIX10.06N/A
N/A
MFS Emerging Markets Equity Research I
LISOX13.44-0.01
-0.07%
Lazard International Strategic Eq Open

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+2.44%
CRSP - AUTL
46%
Loosely correlated
+0.44%
BCYC - AUTL
44%
Loosely correlated
+0.72%
IMTX - AUTL
44%
Loosely correlated
+1.47%
NRIX - AUTL
43%
Loosely correlated
+0.36%
BEAM - AUTL
42%
Loosely correlated
+1.33%
More

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with NRIX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.72%
NRIX - BCYC
51%
Loosely correlated
+0.36%
NGNE - BCYC
49%
Loosely correlated
-0.05%
XNCR - BCYC
49%
Loosely correlated
-0.13%
RGNX - BCYC
48%
Loosely correlated
+0.77%
SYRE - BCYC
48%
Loosely correlated
-0.54%
More